Merriman Capital Initiates on OptimizeRx Corporation with a Buy Rating


View photo


SAN FRANCISCO - July 14, 2014 - Merriman Capital, Inc. ("Merriman"), a wholly owned subsidiary of Merriman Holdings, Inc. (MERR), announced that it has initiated equity research coverage of OptimizeRx Corporation (OPRX) with a Buy rating and a $3.00 price target.

OptimizeRx Corporation provides software solutions that offer pharmaceutical manufacturers direct-to-physician channels for communicating and promoting their products. OPRX`s flagship product - SampleMD - allows doctors to access sample vouchers, co-pay coupons, and other patient support through their e-prescribe systems to search, print, or electronically dispense drug samples directly to patients, as well as a network of pharmacies.  OptimizeRx was founded in 2007 and is headquartered in Rochester, Michigan.


About Merriman Capital, Inc.

Merriman Capital, Inc. is a full service investment bank and Broker-Dealer that facilitates efficient capital formation through a proprietary digital network, and offers Capital Markets Advisory and comprehensive Corporate Brokerage services for public and private companies. The firm also provides equity and options execution services for sophisticated investors and differentiated research for high growth companies. Merriman Capital, Inc. is a wholly owned brokerage subsidiary of Merriman Holdings, Inc. (MERR) and is a leading advisory firm for publicly traded, high-growth companies.

Digital Capital Network, powered by Merriman Capital, is a capital marketplace that enables highly targeted and more efficient execution of transactions. Please visit our website for more information on how you can be a part of our Digital Capital Network:

Merriman Capital, Inc. is a registered broker-dealer and member of The Financial Industry Regulatory Authority (FINRA) and the Securities Investor Protection Corporation (SIPC)

Note to Investors

This press release contains certain forward-looking statements based on our current expectations, forecasts and assumptions that involve risks and uncertainties. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity. Forward-looking statements in this release are based on information available to us as of the date hereof. Our actual results may differ materially from those stated or implied in such forward-looking statements, due to risks and uncertainties associated with our business, which include the risk factors disclosed in our Form 10-K filed on March 31, 2014. Forward-looking statements include statements regarding our expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "should," and "would" or similar words. We assume no obligation to update the information included in this press release, whether as a result of new information, future events or otherwise. The Form 10-K filed on March 31, 2014, together with this press release and the financial information contained herein, are available on our website, Please click on "Investor Relations."
# # #

At Merriman:

Brian Murphy
Equity Research
(646) 292-1411

Adriana Piltz
Director of Research
Merriman Capital, Inc.
(646) 292-1424

Howard Bernstein
Chief Compliance Officer
Merriman Capital, Inc.
(415) 262-1377

For Disclosures please see full report in the link above.


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Merriman Holdings Inc. via GlobeNewswire

View Comments (0)